Laura Joszt, MA

Laura Joszt headshot

Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including Population Health, Equity & Outcomes; Evidence-Based Oncology™; and The Center for Biosimilars®. She has been working on AJMC since 2014 and has been with AJMC’s parent company, MJH Life Sciences®, since 2011.

She has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.

Articles by Laura Joszt, MA

At the spring live meeting of the ACO & Emerging Healthcare Delivery Coalition in Scottsdale, Arizona, attendees heard presentations and participated in workshops that discussed better integration of care, improved use of technology, and the future of healthcare and the Affordable Care Act.

Cost, biosimilars, and technology dominated the conversations when managed care pharmacists, health plan administrators, physicians, and more gathered for the AMCP Managed Care & Specialty Pharmacy Annual Meeting in San Francisco, April 19-22, 2016.

The current reactive healthcare system is driving digital health innovations, Yoona Kim, PharmD, PhD, head of clinical modeling and analytics with Proteus Digital Health, said at the AMCP Managed Care & Specialty Pharmacy Annual Meeting 2016.

As healthcare moves to value-based arrangements and delivery models like accountable care organizations (ACOs), the benefit of incorporating a pharmacist can be overlooked. Tina Joseph, PharmD, BCACP, and Reena Jones, PharmD, CPh, both from Nova Southeastern University, outlined how pharmacists can be integrated into ACOs in order to improve care and patient satisfaction, while reducing cost.

The specialty pharmacy industry is unique in many ways, but the price growth for these drugs is no longer sustainable, Steve Miller, MD, senior vice president and chief medical officer of Express Scripts, said during a pre-meeting session of AMCP Managed Care & Specialty Pharmacy Annual Meeting 2016.

At the end of February, Ted Okon, MBA, executive director of the Community Oncology Alliance (COA), answered questions on Twitter about the latest trends in cancer care and discussed COA’s concerns with the president’s moonshot initiative and the 340B drug pricing program.

Anthony D. Slonim, MD, DrPH, president and chief executive officer for Renown Health and chair of The American Journal of Managed Care (AJMC)’s ACO and Emerging Healthcare Delivery Coalition, spoke to AJMC about what it means to be a physician leader, the industry’s move to population health, the ACO Coalition, and more.

Pay-for-performance (P4P) programs have the potential to improve overall quality of care and the prevalence of these programs has increased in the last 15 years. Here are 5 things to know about P4P and how it can impact healthcare in the move to value-based care.



Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo